Abhinav Kumar

A differentiated CDMO play with full-service capabilities and a strong focus on ‘Development’ across multiple technology platforms.

• Lead licensing and commercial sales for our injectable portfolio for the US and European market.
• Executed 8 deals with an annual revenue impact of $25 million; onboarded 3 marquee partners for the U.S. market.
• Lead and drive collaboration with internal teams and partners to meet annual sales targets and expected timelines, managing an annual P&L of $45M.

Pandorum is a biotech startup working in the field of tissue engineering and cell-derived therapy.

• Build a strategic alliance with pharma companies for out-licensing/commercializing Pandorum's product pipeline; support Series B fundraising, and lead discussions with strategic investors.
• Map the global competitive landscape of cell-derived exosome therapy and develop an entry strategy.
• Build a licensing and valuation model for its assets.

Biocon Biologics is a fully integrated 'pure-play' biosimilars organization in the world.

• Led business development, business strategy, and strategic alliances for Africa, MENA, Turkey, Russia, CIS, APAC, and India.
• Successfully led and executed over 20 commercial deals, leading to market entry in over 20 new markets, as well as over 10 new product launches within existing markets, resulting in an additional revenue opportunity of $20M.
• Selected as part of the "Top 100 Talents" at Biocon.

U.S. based subsidiary of Jubilant Pharma

• Assessed and secured products for the US and European markets from external sources, consistent with Jubilant's strategic interests through licensing and collaboration
• 8 in-licensing deals were signed with partners during my stint at Jubilant.
• Built a strong working relationship with partners globally, including Taiwan, South Korea, Latin America, Israel, Europe, and the US.

Key Projects:

• Commercial due diligence of a target pharma player for Quadria Capital, a leading global private equity player, resulting in an investment of $80M.
• Assessment of target pharma players for ICICI Ventures and Sequoia Capital.
• Go-to-market strategy for Halyard, a US-based medical device company (awarded Best Project of the Year), and Abbott.

Key Projects:

• Acquisition of a Russian pharma player for a major India-based pharma player.
• Detailed landscaping of the medical device industry for a leading medical device company in the Latin American market.
• Project with CII to identify opportunities to improve India's competitiveness vis-à-vis China.

• Facilitated setting up strategic goals for key markets by working with the CEO and Business Heads of India, Russia, and CIS markets.